Merck beats on revenue boosted by Keytruda sales, but posts quarterly loss due to Prometheus deal

[ad_1] Merck on Tuesday reported second-quarter revenue that topped expectations on strong sales of its blockbuster cancer drug Keytruda and HPV vaccine Gardasil. The pharmaceutical giant posted a quarterly loss, however, due to charges associated with the company’s acquisition of Prometheus Biosciences earlier this year.  Merck swung to a net loss of $5.98 billion, or…

Read More

Illumina hit with record $476 million fine for closing Grail deal without EU approval

[ad_1] Rafael Henrique | Lightrocket | Getty Images European Union regulators on Wednesday fined Illumina a record 432 million euros ($476 million) for closing its acquisition of cancer test developer Grail without first securing regulatory approval.  The fine from the European Commission, the EU’s executive body, amounts to 10% of San Diego-based Illumina‘s turnover. That…

Read More

Why Hairdressers, Beauticians, Accountants Are At High Risk Of Ovarian Cancer? Study Reveals

[ad_1] The study, published online in the journal Occupational & Environmental Medicine, was conducted on 1,388 women aged 18-79, of which 491 had epithelial ovarian cancer and 897 didn’t. Researchers from the University of Montreal in Canada calculated participants’ exposure to specific agents in the workplace, and the relationship between exposure to each of…

Read More